<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011984</url>
  </required_header>
  <id_info>
    <org_study_id>recam2013_eucatech</org_study_id>
    <secondary_id>ECT024ResiCSfaRegV10</secondary_id>
    <nct_id>NCT02011984</nct_id>
  </id_info>
  <brief_title>Multicentric Non-randomized Investigation of RESISTANT Camouflage Stent-system</brief_title>
  <acronym>RECAM</acronym>
  <official_title>Multicentric Non-randomized Investigation of RESISTANT Camouflage Stent-system in Peripheral Superficial Femoral Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eucatech AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eucatech AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-randomized multicenter post-market study to confirm the long-term safety and&#xD;
      effectiveness of the CE-approved Camouflage-coated self-expandable RESISTANT Camouflage stent&#xD;
      system for revascularization of de novo stenotic lesions in the superficial femoral artery in&#xD;
      100 compliant patients suitable for stent angioplasty.&#xD;
&#xD;
      The CE-approved device will be used according to its intended use. Beyond the standard of&#xD;
      care no further interventions are scheduled. Therefore, this trial is subject to the&#xD;
      exception to the rule §23b of the German Medical Device Act (MPG), which includes the&#xD;
      national implementation of EC directive 93/42/EEC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this non-randomized post-market clinical follow-up study is to confirm long-term&#xD;
      safety and effectiveness of the CE-approved Camouflage-coated self expandable RESISTANT&#xD;
      Camouflage stent system for revascularization of de novo stenotic lesions in superficial&#xD;
      femoral artery in 120 compliant patients suitable for stent angioplasty. The primary end&#xD;
      point is the target lesion revascularization after 12 months. Further follow-ups are&#xD;
      scheduled at discharge, 30 days, 6 and 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Target lesion revascularization (TLR)</measure>
    <time_frame>12 months</time_frame>
    <description>Target lesion revascularization (TLR) rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>24 hours</time_frame>
    <description>Adverse Event rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>48 hours</time_frame>
    <description>Adverse Event rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>6 months</time_frame>
    <description>Adverse Event rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse Event rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>24 months</time_frame>
    <description>Adverse Event rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>24 hours</time_frame>
    <description>The ability to successfully complete stent angioplasty and achieve a residual diameter stenosis of ≤ 30 %.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>24 hours</time_frame>
    <description>Procedural success rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Impairment Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in Walking Impairment Questionnaire scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Impairment Questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in Walking Impairment Questionnaire scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford classification</measure>
    <time_frame>48 hours</time_frame>
    <description>Change from baseline in Rutherford stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford classification</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in Rutherford stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford classification</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in Rutherford stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford classification</measure>
    <time_frame>24 months</time_frame>
    <description>Change from baseline in Rutherford stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (SF-36 questionnaire)</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in health-related quality of life (SF-36 questionnaire scores)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of lesions that reach endpoint without TLR or with stenosis &lt; 50% on duplex ultrasonography (PSVR (Peak Systolic Velocity Ratio) &lt; 2.4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of lesions that reach endpoint without TLR or with stenosis &lt; 50% on duplex ultrasonography (PSVR (Peak Systolic Velocity Ratio) &lt; 2.4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of lesions that reach endpoint without TLR or with stenosis &lt; 50% on duplex ultrasonography (PSVR (Peak Systolic Velocity Ratio) &lt; 2.4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle brachial index (ABI)</measure>
    <time_frame>48 hours</time_frame>
    <description>Change from baseline in Ankle brachial index (ABI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle brachial index (ABI)</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in Ankle brachial index (ABI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle brachial index (ABI)</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in Ankle brachial index (ABI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle brachial index (ABI)</measure>
    <time_frame>24 months</time_frame>
    <description>Change from baseline in Ankle brachial index (ABI)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>peripheral artery disease</arm_group_label>
    <description>de novo stenotic lesions in superficial femoral artery</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with de novo stenotic lesions in the superficial femoral artery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 18 to 95 years&#xD;
&#xD;
          -  Male or non-pregnant female&#xD;
&#xD;
          -  De novo lesions&gt;70% or occlusions in the SFA (Superficial Femoral Artery) arteries&#xD;
             suitable for stent angioplasty&#xD;
&#xD;
          -  Max. 1 lesion within each leg should be treated as study lesions&#xD;
&#xD;
          -  Lesions length range from ≥3 cm to ≤18 cm&#xD;
&#xD;
          -  A patent inflow artery free from significant lesions (&gt;50 % stenosis) as confirmed by&#xD;
             angiography. Treatment of target lesion acceptable after successful treatment of&#xD;
             inflow artery lesions.&#xD;
&#xD;
          -  Reference vessel diameter ≥3 mm and ≤ 7 mm&#xD;
&#xD;
          -  Successful guide wire passage of the lesion&#xD;
&#xD;
          -  Symptomatic peripheral artery disease (Rutherford stage 2 to 5)&#xD;
&#xD;
          -  Patient is willing to provide informed consent and comply with the required follow-up&#xD;
             visits, testing schedule, and medication regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients for whom an anti-platelet therapy, anticoagulants or thrombolytics are&#xD;
             contraindicated&#xD;
&#xD;
          -  Patients presenting a lasting intraluminal thrombosis at the lesion after a&#xD;
             thrombolytic therapy&#xD;
&#xD;
          -  Perforation at the location of the angioplasty characterized by secretion of the&#xD;
             contrast medium&#xD;
&#xD;
          -  Aneurysm of the artery to be treated&#xD;
&#xD;
          -  All common contraindications for a PTA (Percutaneous Transluminal Angioplasty)&#xD;
&#xD;
          -  Contraindications for stent angioplasty&#xD;
&#xD;
          -  Hypersensitivity/allergy to nickel-titanium&#xD;
&#xD;
          -  Hypersensitivity/allergy to any of the components of the delivery &amp; dilation system&#xD;
&#xD;
          -  Severe renal insufficiency (creatinine&gt;2.0 mg/dL or glomerular filtration rate &lt; 60&#xD;
             ml/min/1.73)&#xD;
&#xD;
          -  Uncorrected bleeding disorder&#xD;
&#xD;
          -  Major gastrointestinal bleeding within the last 6 months.&#xD;
&#xD;
          -  Ipsilateral intervention other than target vessel&#xD;
&#xD;
          -  Untreated ipsilateral iliac artery stenosis &gt;70 %&#xD;
&#xD;
          -  Previous stenting or prior surgery of the SFA&#xD;
&#xD;
          -  In-stent restenosis&#xD;
&#xD;
          -  Acute myocardial infarct within 72 h&#xD;
&#xD;
          -  Less than one patent crural artery&#xD;
&#xD;
          -  Popliteal stenosis &gt; 70 %&#xD;
&#xD;
          -  Manifest hyperthyroidism&#xD;
&#xD;
          -  Acute onset of symptoms&#xD;
&#xD;
          -  Leg-threatening ischemia&#xD;
&#xD;
          -  Multimorbid patient with poor general condition&#xD;
&#xD;
          -  Pregnant woman or becoming pregnant in &lt; 2 yrs&#xD;
&#xD;
          -  Living more than 100 km apart from the study center&#xD;
&#xD;
          -  Patient actively participating in another investigational device or drug study&#xD;
&#xD;
          -  History of hemorrhagic stroke within 3 months&#xD;
&#xD;
          -  Previous or planned surgical or interventional procedure within 30 days of the&#xD;
             procedure&#xD;
&#xD;
          -  Acute or sub-acute thrombus in target vessel&#xD;
&#xD;
          -  Acute vessel occlusion or sudden symptom onset&#xD;
&#xD;
          -  Lesions in target area requiring atherectomy (or ablative devices), cutting balloons,&#xD;
             cryoplasty balloons, or any other advanced device to facilitate angioplasty balloon or&#xD;
             stent delivery&#xD;
&#xD;
          -  Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting&#xD;
             balloon, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Giese, Phd</last_name>
    <role>Study Chair</role>
    <affiliation>Eucatech AG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Marx, MD</last_name>
    <phone>00497621167333</phone>
    <phone_ext>20</phone_ext>
    <email>c.marx@clinical-evaluation.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uniklinikum Freiburg, Abteilung Röntgendiagnostik</name>
      <address>
        <city>Freiburg</city>
        <state>Baden Württemberg</state>
        <zip>79095</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wulf Euringer, M.D.</last_name>
      <phone>0049 761 270</phone>
      <phone_ext>38580</phone_ext>
      <email>wulf.euringer@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Wulf Euringer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Gießen und Marburg, Diagnostische und Interventionelle Radiologie</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mykhaylo Burbelko, M.D.</last_name>
      <phone>0049 6421 58</phone>
      <phone_ext>65912</phone_ext>
      <email>burbelko@med.uni-marburg.de</email>
    </contact>
    <investigator>
      <last_name>Mykhaylo Burbelko, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta-Krankenhaus, Klinik für Gefäßchrirugie</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein - Westfalen</state>
        <zip>40472</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Kolvenbach, Prof.</last_name>
      <phone>0049 211 9043</phone>
      <phone_ext>301</phone_ext>
      <email>kolvenbach@vkkd-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Kolvenbach, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heinrich Braun Klinikum Zwickau, Radiologie und Neuroradiologie</name>
      <address>
        <city>Zwickau</city>
        <state>Sachsen</state>
        <zip>08060</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Thalwitzer, M.D.</last_name>
      <phone>0049 375</phone>
      <phone_ext>-4854/-4855</phone_ext>
      <email>irad@hbk-zwickau.de</email>
    </contact>
    <investigator>
      <last_name>Jörg Thalwitzer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CCP - Istituto di Cura &quot;Città di Pavia&quot;</name>
      <address>
        <city>Pavia</city>
        <state>Lombardy</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesare Massa Saluzzo, M.D.</last_name>
      <phone>0039 3349419996</phone>
      <email>segreteria@centroendovascolare.it</email>
    </contact>
    <investigator>
      <last_name>Cesare Massa Saluzzo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2013</study_first_posted>
  <last_update_submitted>February 10, 2015</last_update_submitted>
  <last_update_submitted_qc>February 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

